Quest Diagnostics Inc (NYSE:DGX) – Equities research analysts at KeyCorp lifted their Q3 2020 earnings per share (EPS) estimates for Quest Diagnostics in a note issued to investors on Tuesday, July 28th. KeyCorp analyst D. Hooker now forecasts that the medical research company will post earnings per share of $3.37 for the quarter, up from their previous forecast of $1.78. KeyCorp also issued estimates for Quest Diagnostics’ Q4 2020 earnings at $3.27 EPS, FY2020 earnings at $9.00 EPS and FY2021 earnings at $9.10 EPS.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, July 23rd. The medical research company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.01. Quest Diagnostics had a net margin of 9.99% and a return on equity of 13.78%. The company had revenue of $1.83 billion for the quarter, compared to analysts’ expectations of $1.81 billion. During the same quarter in the previous year, the company earned $1.73 EPS. Quest Diagnostics’s revenue for the quarter was down 6.3% on a year-over-year basis.

A number of other analysts also recently issued reports on the stock. Barclays lifted their price target on shares of Quest Diagnostics from $93.00 to $99.00 and gave the company an “equal weight” rating in a report on Thursday, April 23rd. Citigroup lifted their price target on shares of Quest Diagnostics from $130.00 to $151.00 and gave the company a “buy” rating in a report on Friday, July 24th. Wolfe Research upgraded shares of Quest Diagnostics from an “underperform” rating to a “market perform” rating and set a $116.00 price target on the stock in a report on Monday, April 27th. Cfra downgraded shares of Quest Diagnostics from a “strong-buy” rating to a “hold” rating and reduced their price target for the company from $140.00 to $106.00 in a report on Wednesday, April 22nd. Finally, BofA Securities upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and set a $142.00 price target on the stock in a report on Tuesday, July 14th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $124.84.

DGX opened at $127.07 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.21 and a current ratio of 1.29. The stock has a market cap of $17.07 billion, a price-to-earnings ratio of 23.06, a price-to-earnings-growth ratio of 0.95 and a beta of 1.38. The firm’s fifty day moving average is $117.08 and its 200 day moving average is $107.37. Quest Diagnostics has a fifty-two week low of $73.02 and a fifty-two week high of $131.81.

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th were issued a dividend of $0.56 per share. The ex-dividend date of this dividend was Tuesday, July 7th. This represents a $2.24 annualized dividend and a yield of 1.76%. Quest Diagnostics’s payout ratio is 34.15%.

A number of large investors have recently modified their holdings of DGX. Wealthcare Advisory Partners LLC grew its holdings in Quest Diagnostics by 81.0% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 342 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 153 shares during the last quarter. Procyon Private Wealth Partners LLC bought a new position in Quest Diagnostics during the 4th quarter valued at about $29,000. Valeo Financial Advisors LLC bought a new position in Quest Diagnostics during the 1st quarter valued at about $30,000. FinTrust Capital Advisors LLC grew its holdings in Quest Diagnostics by 329.9% during the 1st quarter. FinTrust Capital Advisors LLC now owns 374 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 287 shares during the last quarter. Finally, RMR Wealth Builders bought a new position in Quest Diagnostics during the 4th quarter valued at about $42,000. Institutional investors own 88.88% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also: What are the benefits of investing in REITs?

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.